Salvage Therapy with Gilteritinib Plus Venetoclax for FLT3-ITD-Positive AML: A Case Report and Literature Review
Journal Title: Diseases & Research - Year 2022, Vol 2, Issue 1
Abstract
FMS-like tyrosine kinase 3 (FLT3) mutations occur in around 30% of patients in acute myeloid leukemia (AML), and are generally associated with unfavorable outcomes. Gilteritinib is a highly specific second-generation class I FLT3 inhibitor, which can efficiently and specifically bind to the kinase domain. It can inhibit FLT3 receptor signal transduction to inhibit the growth of AML cells, reduce cell proliferation and induce apoptosis. It has been demonstrated that single-agent gilteritinib therapy is superiority to salvage chemotherapy (SC) in relapsed or refractory (R/R) FLT3-mutated AML based on significantly longer overall survival (OS). To evaluate the clinical efficacy of combinatorial targeted therapeutic approaches, here we reported a case of refractory AML with FLT3-ITD mutation that was treated with gilteritinib combined with BCL2 inhibitor venetoclax regimen, and bone marrow aspiration performed after 2 cycles of the targeted therapy was compatible with complete remission (CR). During the whole treatment process, no serious adverse events were observed. However, the primary disease recurred 1 month after achieving CR state, and the NRAS mutation developed. The patient eventually died of severe infection and multiple organ failure. Despite this, it was demonstrated that that gilteritinib combined with venetoclax can be a safe and effective regimen in R/R AML with FLT3 mutations and activating RAS/MAPK pathway mutations may confer resistance to gilteritinib.
Authors and Affiliations
Dian Lou, Li Liu, Weiwei Qin
Keywords
Related Articles
- EP ID EP740157
- DOI 10.54457/DR.202201002
- Views 32
- Downloads 1
Role of Various Immune Cells in the Tumor Microenvironment
The tumor microenvironment (TME) has numerous promotive and suppressive effects on tumor growth. The TME harbors adaptive and innate immune cells such as T cells, B cells, natural killer (NK) cells, macrophages, neutroph...
Salvage Therapy with Gilteritinib Plus Venetoclax for FLT3-ITD-Positive AML: A Case Report and Literature Review
FMS-like tyrosine kinase 3 (FLT3) mutations occur in around 30% of patients in acute myeloid leukemia (AML), and are generally associated with unfavorable outcomes. Gilteritinib is a highly specific second-generation cla...
Dendritic Cell Subsets: The Next Target for Pregnant Complications?
Dendritic cells (DCs) are professional antigen-presenting cells with both immune stimulatory and regulatory functions. DCs are critical players in pregnancy, whose dysregulation is associated with multiple pregnancy-rela...
Human Glioma Nude Mouse Xenograft Model in situ
Backgrounds Surgery and chemotherapy are difficult because of the specific location of the glioma. The establishment of a suitable in situ model of glioma is the premise of the treatment of glioma. 8 week-old female BALB...
Determination of mRNA Targets of miR-376c within the RNA-Induced Silencing Complex
Background The focus of the present study was to establish an easy combined method based on the MirTrap system together with a mRNA array to efficiently define target mRNAs which can be bound by miR-376 within the RNA-in...